Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation

T. Iino, H. Gondo, Y. Ohno, H. Minagawa, H. Iwasaki, T. Maruyama, H. Nakashima, Y. Niho

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)

    Abstract

    A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive to acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.

    Original languageEnglish
    Pages (from-to)1185-1188
    Number of pages4
    JournalBone Marrow Transplantation
    Volume18
    Issue number6
    Publication statusPublished - Dec 1996

    All Science Journal Classification (ASJC) codes

    • Hematology
    • Transplantation

    Fingerprint Dive into the research topics of 'Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation'. Together they form a unique fingerprint.

    Cite this